≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

See its core counterpart C3_CERVIX_SQUAM_EXALLC for full statistics.

Squamous cell neoplasms and carcinoma of cervix

Endpoint Browser

C3_CERVIX_SQUAM

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

only females

293373

2. Check conditions

None

293373

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cancer registry: Topography ICD-O-3 — C53
  • Cancer registry: Morphology ICD-O-3 — 8070
  • Cancer registry: Behaviour codes — 3

1 out of 7 registries used, show all original rules.

232

4. Check minimum number of events

None

232

5. Include endpoints

None

232

6. Filter based on genotype QC (FinnGen only)

232

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF8

Similar endpoints

↥

List of similar endpoints to Squamous cell neoplasms and carcinoma of cervix based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Similar with more cases:

Venn diagram with a set fully inside an highlighted set Similar with less cases:

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 232 232 -
Unadjusted period prevalence (%) 0.08 0.08 -
Median age at first event (years) 43.06 43.06 -

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
225
Matched controls
2248
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8070/3-C53.9
ICD-O-3
Squamous cell carcinoma, NOS, of cervix uteri
+∞
204.7
164
*
C53.11
ICD-10 Finland
Squamous cell carcinoma and exocervix
+∞
128.9
111
*
C53.01
ICD-10 Finland
Squamous cell carcinoma of the endocervix
1650.9
107.6
96
*
128
Kela drug reimbursment
Cancers of female genital organs
91.4
64.9
70
11
ULA02
NOMESCO Finland
Kolposcopy
11.8
51.1
109
166
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
20.2
47.0
73
52
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
9.9
46.8
112
204
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
13.6
46.7
88
101
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
9.3
40.2
96
166
8070/3-C53.1
ICD-O-3
Squamous cell carcinoma, NOS, of exocervix
+∞
36.4
34
*
LCD30
NOMESCO Finland
Radical hysterectomy
406.9
36.0
35
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
43.9
30.4
37
10
LCD31
NOMESCO Finland
Radical laparoscopic hysterectomy
+∞
29.8
28
*
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
74.1
28.8
32
5
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
165.4
28.3
29
*
WF002
NOMESCO Finland
Radical radiotherapy
20.0
26.5
40
24
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
66.1
25.7
29
5
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
15.9
25.5
42
32
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
79.3
25.4
28
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
73.0
23.4
26
*
8070/3-C53.0
ICD-O-3
Squamous cell carcinoma, NOS, of endocervix
+∞
23.3
22
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
19.8
22.6
34
20
ZXC96
NOMESCO Finland
Robot assisted procedure
22.8
21.0
30
15
C53.00
ICD-10 Finland
Malignant tumor of endocervix without histology
230.2
20.9
21
*
B01AB10
ATC
tinzaparin; parenteral
9.3
20.5
44
57
LDA10
NOMESCO Finland
Curettage of cervix uteri
9.9
20.3
42
51
ZX080
NOMESCO Finland
Image guided radiotherapy
27.6
20.1
27
11
ZX095
NOMESCO Finland
Combined chemoradiotherapy
115.2
19.9
21
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
68.7
17.0
19
*
A04AA55
ATC
palonosetron, combinations; systemic
11.7
16.3
30
29
H02AB02
ATC
dexamethasone; systemic
5.6
15.9
49
106
C53.81
ICD-10 Finland
Overall squamous cell carcinoma of the cervix uteri
+∞
15.8
15
*
C53.10
ICD-10 Finland
Malignant tumor of the exocervix without histology
+∞
15.8
15
*
A04AA01
ATC
ondansetron; systemic, rectal
6.9
15.6
40
68
N87.2
ICD-10 Finland
Severe cervical dysplasia, not elsewhere classified
11.3
15.5
29
29
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
8.8
15.3
33
43
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
34.3
15.1
19
6
PJ5AQ
NOMESCO Finland
Sentinell lymphnode SPECT with low dose CT
+∞
14.7
14
*
8310
FHL
Radical hysterectomy (includes lymph node removal)
+∞
14.7
14
*
C53.1
ICD-10 Finland
Malignant neoplasm: Exocervix
+∞
14.7
14
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.8
14.2
42
86
18099
ICD-8 Finland
Malignant neoplasm of cervix uteri
80.1
13.7
15
*
JN5JS
NOMESCO Finland
Extensive PET-MRI of body metabolism
+∞
13.7
13
*
C53.0
ICD-10 Finland
Malignant neoplasm: Endocervix
+∞
13.7
13
*
C53.91
ICD-10 Finland
Squamous cell carcinoma in an unspecified location in the cervix
148.5
13.6
14
*
LEB00
NOMESCO Finland
Biopsy of vagina
15.1
13.6
22
16
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
24.3
13.1
18
8
A03FA01
ATC
metoclopramide; systemic, rectal
3.3
12.8
78
312
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
3.8
12.7
60
197
1801A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Exocervix
+∞
12.6
12
*
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.8
12.4
114
596
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
28.5
12.2
16
6
JN4BD
NOMESCO Finland
Extensive body CT
4.9
11.8
40
95
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.7
11.7
27
39
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
68.6
11.7
13
*
C53
ICD-10 Finland
Malignant neoplasm of cervix uteri
+∞
11.5
11
*
C53.90
ICD-10 Finland
Malignant tumor in unspecified localization in cervix uteri without histology
+∞
11.5
11
*
1800A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Endocervix
+∞
11.5
11
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
8.8
11.4
24
30
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
29.7
10.9
14
5
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
+∞
10.5
10
*
LAG11
NOMESCO Finland
Laparoscopic oophoropexy
+∞
10.5
10
*
PJA01
NOMESCO Finland
Laparoscopic sentinel node excision
24.7
10.4
14
6
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
42.0
10.1
12
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
21.2
9.9
14
7
WW500
NOMESCO Finland
Blood transfusion
8.7
9.6
20
25
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
8.9
9.3
19
23
N02AA05
ATC
oxycodone; systemic
3.5
9.0
44
146
B01AB05
ATC
enoxaparin; parenteral
2.5
8.7
83
423
UKC02
NOMESCO Finland
Cystoscopy
3.8
8.4
36
107
C53.99
ICD-10 Finland
Malignant tumor in unspecified localization in cervix, unspecified histology
+∞
8.4
8
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.4
8.2
87
465
Z51.5
ICD-10 Finland
Palliative care
5.4
8.2
24
49
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
7.0
8.1
19
29
ZX090
NOMESCO Finland
Other technic of radiotherapy
7.0
8.1
19
29
WZC30
NOMESCO Finland
Teaching
3.5
7.8
37
120
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
15.7
7.8
12
8
WF049
NOMESCO Finland
Radiotherapy of metastasis
15.7
7.8
12
8
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
15.7
7.8
12
8
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
46.6
7.8
9
*
A04AD12
ATC
aprepitant; systemic
8.1
7.5
16
21
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
82.6
7.5
8
*
D06.0
ICD-10 Finland
Carcinoma in situ: Endocervix
20.8
7.2
10
5
N93.9
ICD-10 Finland
Abnormal uterine and vaginal bleeding, unspecified
7.4
7.1
16
23
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
11.4
6.9
12
11
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
6.7
20
42
L03AA02
ATC
filgrastim; parenteral
10.5
6.6
12
12
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
18.6
6.3
9
5
TLW99
NOMESCO Finland
Other minor surgical procedure in gynaecology
6.6
6.3
15
24
18011
ICD-8 Finland
NA
+∞
6.3
6
*
JN5KS
NOMESCO Finland
Very extensive PET-MRI of body metabolism
+∞
6.3
6
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.1
6.3
16
28
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
27.5
6.3
8
*
LBE20
NOMESCO Finland
Laparoscopic bilateral salpingectomy
7.0
6.1
14
21

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
53
162
3.94
15.51
1.4
1.4
—
—
—
0
0
26
49
5.85
13.58
2.4
1.9
—
—
—
0
0
107
609
2.40
9.66
3.7
3.0
—
—
—
0
0
112
686
2.22
8.14
6.5
3.9
33.4
36.0
g/l
3.53
104
631
13
22
6.20
7.46
1.1
1.1
—
—
—
0
0
119
798
2.01
6.34
2.8
2.0
—
—
—
0
0
85
514
2.03
5.98
1.5
1.5
—
—
—
0
0
70
405
2.04
5.49
6.7
3.7
—
—
—
0
0
82
506
1.96
5.35
4.0
3.1
81.2
61.5
e6/l
0.17
67
380
10
20
5.18
4.82
1.1
1.0
—
—
—
0
0
39
188
2.29
4.81
1.9
1.4
—
—
—
0
0
87
568
1.85
4.67
3.8
2.0
—
—
—
0
0
58
331
2.00
4.65
3.3
2.7
494.3
533.8
mosm/kgh2o
0.95
53
286
69
435
1.83
4.06
12.2
6.9
—
—
—
0
0
69
460
1.71
3.28
4.0
2.9
0.6
0.5
e6/l
0.25
57
339
14
49
2.98
3.25
5.4
4.9
—
—
—
0
0
28
140
2.14
3.16
7.0
2.9
—
—
—
0
0
86
614
1.64
3.13
5.5
7.6
1.1
1.2
inr
0.35
20
194
6
8
7.66
3.07
1.8
1.6
14.4
17.8
ug/l
—
6
8
55
353
1.73
2.97
2.7
2.7
10.0
9.1
e6/l
0.09
50
315
126
997
1.58
2.93
5.2
4.0
6.6
6.5
mmol/l
0.26
120
906
85
618
1.59
2.82
5.0
3.6
280.3
87.0
e6/l
0.87
68
414
129
1042
1.54
2.64
15.2
8.8
4.1
4.0
e9/l
0.32
121
914
115
907
1.53
2.62
6.3
5.1
0.0
0.0
estimate
0.00
15
174
115
912
1.52
2.52
4.4
3.7
0.0
0.0
estimate
0.00
15
168
65
457
1.59
2.44
3.7
2.8
—
—
—
0
0
156
1753
0.66
2.16
3.7
4.0
4.9
4.8
mmol/l
0.52
151
1640
30
177
1.80
2.15
11.5
3.9
1.0
1.0
mmol/l
0.15
30
156
93
724
1.47
2.15
4.3
3.4
—
—
—
0
0
146
1242
1.47
2.12
6.9
4.6
3094.0
3150.7
e6/l
—
6
21
82
629
1.47
2.02
4.9
3.1
2.3
2.4
mmol/l
0.60
76
557
5
139
0.35
1.96
1.6
1.3
—
44.5
—
0
6
26
152
1.80
1.93
4.6
3.1
—
—
—
0
0
17
86
2.05
1.90
6.3
3.9
—
—
—
0
0
13
59
2.27
1.88
2.1
1.6
4.8
1.4
ug/l
0.59
13
51
156
1738
0.69
1.87
3.7
4.0
1.5
1.6
mmol/l
0.99
150
1619
56
404
1.51
1.85
3.8
3.5
—
—
—
0
0
147
1280
1.41
1.70
6.5
4.4
—
—
—
0
0
19
105
1.88
1.69
12.8
6.0
—
—
—
0
0
33
483
0.63
1.67
2.1
1.6
1.7
1.4
mmol/l
1.50
25
411
7
157
0.43
1.62
3.1
2.3
—
20.4
—
0
6
163
1785
0.71
1.56
3.9
4.4
2.9
2.9
mmol/l
0.15
153
1655
5
15
3.38
1.53
1.0
1.2
—
—
—
0
0
151
1670
0.73
1.49
3.4
3.6
1.4
1.2
mmol/l
1.83
144
1548
9
179
0.48
1.47
1.3
1.8
381.7
371.6
nmol/l
—
9
163
5
16
3.17
1.44
2.4
3.2
—
—
—
0
0
22
135
1.70
1.42
6.0
6.3
93.3
96.1
%
0.68
22
130
94
780
1.34
1.38
6.6
5.0
1.2
1.2
mmol/l
1.25
89
713
16
91
1.81
1.32
7.1
6.3
25.3
24.7
mmol/l
0.34
16
86
10
48
2.13
1.29
3.2
2.3
—
—
—
0
0
8
36
2.26
1.25
2.0
2.4
22.7
23.9
mmol/l
—
8
28
52
402
1.38
1.18
1.5
1.7
1.5
0.9
mg/l
0.69
43
307
17
103
1.70
1.16
2.5
2.1
194.6
4096.0
u/l
—
10
41
31
220
1.47
1.12
2.2
1.7
28.4
29.1
s
0.51
31
212
8
41
1.98
1.10
2.0
2.5
7.2
7.2
mmol/l
—
8
41
195
1833
1.40
1.08
22.9
12.5
28.5
19.9
mg/l
2.62
170
1405
29
396
0.69
1.04
1.6
1.4
2.5
2.1
g/l
0.59
19
243
9
47
1.95
1.03
2.0
2.8
6.6
10.0
mg/l
—
9
42
32
233
1.43
1.02
1.6
1.9
73.1
108.6
ug/g
0.66
25
179
9
49
1.87
1.00
2.4
3.0
—
—
—
0
0
33
244
1.41
0.98
2.5
2.0
—
—
—
0
0
51
407
1.32
0.95
4.3
3.6
1.0
1.0
kg/l
—
8
60
6
27
2.25
0.94
1.2
1.2
—
—
—
0
0
18
118
1.57
0.94
3.5
2.4
67.3
67.1
g/l
0.05
18
110
5
101
0.48
0.92
1.0
1.1
—
—
—
0
0
103
904
1.25
0.91
4.7
3.6
0.0
0.0
estimate
0.00
15
174
14
87
1.65
0.90
5.4
4.5
—
—
—
0
0
8
42
1.94
0.89
2.0
2.5
1.8
1.4
mmol/l
—
8
42
14
88
1.63
0.86
1.9
2.4
—
—
—
0
0
134
1217
1.24
0.85
3.1
3.4
—
—
—
0
0
22
155
1.46
0.85
8.4
5.8
10.6
12.2
kpa
1.06
22
148
22
155
1.46
0.85
8.4
5.8
5.1
5.1
kpa
0.08
22
148
16
106
1.55
0.81
4.6
3.2
79.4
72.6
e9/l
0.31
11
82
56
464
1.27
0.80
3.9
3.5
—
—
—
0
0
51
418
1.28
0.79
2.6
2.2
3.5
3.0
mg/l
0.61
42
362
89
780
1.23
0.78
10.2
8.6
0.0
0.0
e9/l
0.50
75
638
164
1738
0.81
0.74
4.4
4.1
6.0
5.8
mmol/l
1.13
153
1604
58
489
1.25
0.72
4.5
3.8
0.0
0.0
estimate
0.00
15
171
12
77
1.59
0.70
1.4
1.2
—
—
—
0
0
5
27
1.87
0.69
2.0
3.1
2.9
1.6
%
—
5
21
63
540
1.23
0.67
3.6
3.7
7.4
7.4
ph
0.18
12
100
7
43
1.65
0.67
7.0
6.4
1.7
1.1
mmol/l
—
7
38
8
127
0.62
0.66
2.5
1.6
—
—
—
0
0
5
29
1.74
0.64
1.8
2.0
—
—
—
0
0
100
902
1.19
0.63
3.1
2.9
170.8
84.7
ug/l
1.50
94
839
5
30
1.68
0.62
1.8
2.0
101.0
106.3
mmol/l
—
5
30
5
30
1.68
0.62
1.8
2.0
3.7
4.0
mmol/l
—
5
30
30
373
0.78
0.61
1.4
1.3
19.5
7.9
u/ml
0.42
12
146
6
35
1.73
0.58
1.2
1.3
—
—
—
0
0
9
59
1.55
0.55
9.8
3.7
—
—
—
0
0
17
126
1.38
0.53
1.3
1.3
—
—
—
0
0
168
1755
0.85
0.50
4.5
5.2
1.8
2.5
mu/l
0.53
157
1634
28
342
0.79
0.50
2.0
1.6
—
—
—
0
0
21
164
1.31
0.48
9.5
3.8
—
—
—
0
0
59
520
1.18
0.47
4.5
3.4
—
—
—
0
0
19
242
0.77
0.47
1.6
1.5
—
—
—
0
0
24
192
1.28
0.47
1.4
1.2
—
—
—
0
0
8
116
0.68
0.47
1.6
1.9
0.9
1.5
g/l
—
8
105
70
628
1.16
0.46
3.0
3.6
29.1
35.8
ng/l
0.30
41
388
35
296
1.21
0.44
3.1
3.6
598.2
134.3
ng/l
0.51
25
198
26
213
1.25
0.43
1.8
1.5
—
—
—
0
0
8
57
1.42
0.42
4.9
4.0
—
—
—
0
0
18
227
0.78
0.42
1.8
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
2.0
—
47.8
—
0
8
0
17
0.00
0.41
0.0
9.8
—
0.7
—
0
17
5
34
1.48
0.40
5.0
1.9
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
32.3
—
0
19
12
89
1.37
0.38
8.0
3.1
5.0
5.2
kpa
0.34
12
80
14
180
0.76
0.38
1.4
1.3
—
—
—
0
0
196
1905
1.19
0.38
26.8
13.9
75.1
68.9
umol/l
1.31
196
1905
10
135
0.73
0.37
3.0
2.3
10.4
10.2
g/l
—
10
123
32
372
0.84
0.37
1.4
1.3
13.0
29.8
iu/ml
—
10
132
15
117
1.30
0.36
2.6
2.7
—
—
—
0
0
19
154
1.25
0.35
3.8
3.9
—
—
—
0
0
47
421
1.15
0.32
2.9
3.0
1623.5
218.9
mg/l
0.46
29
251
24
203
1.20
0.31
15.2
18.7
0.9
1.2
inr
—
5
32
41
457
0.88
0.29
1.4
1.2
0.5
2.3
u/ml
1.20
14
133
20
236
0.83
0.28
1.6
1.2
—
—
—
0
0
97
918
1.10
0.26
6.3
5.4
1.6
2.0
e9/l
2.65
90
828
17
142
1.21
0.25
3.9
4.2
1.2
1.2
mmol/l
0.18
17
127
10
126
0.78
0.25
2.1
1.3
—
—
—
0
0
10
79
1.28
0.22
1.6
2.2
1.8
1.0
%
—
10
79
173
1687
1.10
0.22
22.1
13.0
37.0
39.2
%
2.03
129
1271
61
569
1.10
0.22
5.9
5.1
—
—
—
0
0
45
413
1.11
0.22
2.7
2.5
318.9
5135.4
umol/l
1.81
37
352
50
462
1.10
0.21
2.5
2.8
6.5
7.0
mmol/l
0.45
37
379
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
0.9
—
0
10
0
10
0.00
0.21
0.0
1.4
—
2.0
—
0
10
0
12
0.00
0.21
0.0
2.0
—
1.1
—
0
5
48
443
1.11
0.21
4.0
3.7
34.6
8.4
mg/mmol
0.75
33
259
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
16
136
1.19
0.20
2.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
10
122
0.81
0.19
1.6
1.4
—
—
—
0
0
25
278
0.89
0.18
1.2
1.4
380.0
530.1
titre
—
6
67
36
391
0.91
0.17
1.6
1.5
16.5
22.0
nmol/l
2.24
31
332
19
215
0.87
0.17
1.3
1.4
—
—
—
0
0
10
82
1.23
0.17
9.3
4.2
24.9
24.9
mmol/l
—
10
82
5
67
0.74
0.17
1.2
1.3
—
—
—
0
0
5
67
0.74
0.17
1.2
1.3
—
—
—
0
0
5
67
0.74
0.17
1.2
1.3
—
—
—
0
0
5
68
0.73
0.17
1.2
1.3
—
—
—
0
0
133
1366
0.94
0.16
4.0
4.0
16.5
11.2
mm/h
2.25
122
1256
6
79
0.75
0.16
1.0
1.1
—
—
—
0
0
9
80
1.13
0.15
1.2
1.2
—
—
—
0
0
147
1504
0.94
0.15
3.9
4.5
14.8
14.6
pmol/l
0.42
138
1382
25
227
1.11
0.15
1.2
1.2
—
—
—
0
0
14
122
1.16
0.14
8.9
4.9
1.3
1.4
mmol/l
0.08
14
117
16
142
1.14
0.13
1.8
1.4
—
—
—
0
0
194
1916
1.08
0.12
13.8
9.5
25.8
23.2
u/l
0.70
194
1853
194
1917
1.07
0.11
19.2
11.6
—
—
—
0
0
92
893
1.05
0.11
6.5
5.3
0.6
0.5
e9/l
0.47
85
789
96
934
1.05
0.10
6.4
5.7
0.2
0.2
e9/l
0.76
88
838
92
895
1.05
0.10
6.5
5.4
0.0
0.0
e9/l
0.89
84
789
47
449
1.06
0.09
4.3
5.0
—
—
—
0
0
6
58
1.04
0.08
1.0
1.3
—
—
—
0
0
5
62
0.80
0.08
1.6
1.2
—
—
—
0
0
5
62
0.80
0.08
1.0
1.3
—
—
—
0
0
7
66
1.06
0.08
2.1
1.5
—
—
—
0
0
12
130
0.92
0.04
1.4
1.4
—
—
—
0
0
13
140
0.92
0.04
3.1
4.4
0.8
0.8
%
—
6
43
67
657
1.03
0.04
2.7
2.6
—
—
—
0
0
19
200
0.95
0.04
1.5
1.3
—
—
—
0
0
12
129
0.93
0.03
10.2
2.9
107.3
75.9
ng/l
0.42
12
116
38
391
0.97
0.03
2.1
1.8
—
—
—
0
0
12
128
0.93
0.02
3.2
4.6
0.0
0.1
%
—
5
38
15
151
0.99
0.00
1.1
1.1
—
—
—
0
0
33
325
1.02
0.00
1.6
1.7
938.7
1182.3
nmol/l
0.95
26
251
69
687
1.01
0.00
2.0
1.9
83.6
97.3
pmol/l
1.68
47
347
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
14.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
0.3
—
0
7
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
9
99
0.91
0.00
2.1
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
11.0
—
0
9
0
6
0.00
0.00
0.0
1.3
—
75.2
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_CERVIX_SQUAM – Squamous cell neoplasms and carcinoma of cervix

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).